SAN FRANCISCO, Oct. 28, 2013 /PRNewswire/ -- Patients treated with the Boston Scientific (NYSE: BSX) Vessix™ Renal Denervation System experienced a significant and sustained reduction in blood pressure, according to new data presented today at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco. An interim analysis of 139 patients enrolled in the REDUCE-HTN post market study affirms the device safety profile and effective treatment for resistant hypertension.
"In the REDUCE-HTN study, 85 percent of patients treated with the Vessix System experienced a clinically-meaningful decrease in blood pressure," said Professor Horst Sievert, M.D., Ph.D., director of the CardioVascular Center Frankfurt, Sankt Katharinen Hospital in Frankfurt, Germany, and principal investigator in the REDUCE-HTN clinical program. "In my opinion, the large patient cohort and rigorous analysis of the study suggest that renal denervation using bipolar technology will be an important part of the treatment algorithm for a wide variety of patients with resistant hypertension."
Renal denervation with the Vessix System is a minimally-invasive procedure in which a balloon catheter is fed through the arterial vascular system and positioned in the renal arteries, the major blood vessels that lead to the kidneys. The physician then delivers low-power radiofrequency (RF) energy to disrupt the nerves surrounding the renal arteries in which hyperactivity contributes to uncontrolled high blood pressure. The Boston Scientific Vessix System is the only renal denervation system to utilize bipolar energy to disrupt these nerves, providing a more localized and precise approach.
The REDUCE-HTN post market study enrolled 146 patients at 23 centers in Europe, Australia and New Zealand and is evaluating the ability of the Vessix System to reduce blood pressure at six months compared to the pre-treatment baseline blood pressure. Patients enrolled in the program are required to have a systolic blood pressure of at least 160 mmHg despite taking three or more antihypertensive medications.Interim data highlights of the study include:
- A significant 24.6 mmHg reduction in systolic blood pressure (p<.0001) at six months
- A sustained 29.6 mmHg reduction in systolic blood pressure in the subset of patients for whom 12-month data are available
- A clinically-meaningful decrease in office systolic blood pressure at both six and 12 months in 85-percent of patients in the trial
- Success reducing blood pressure in a variety of subgroups, including both men and women, patients with Type-2 diabetes and patients age of 65 or older
- A strong safety profile with no occurrence of prespecified acute safety events and eight procedure-related serious adverse events (5.5 percent) among the 146 patients
- A wide range of anatomies were treated, including accessory renal arteries
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV